Simultaneous monitoring of oxidation, deamidation, isomerization, and glycosylation of monoclonal antibodies by liquid chromatography-mass spectrometry method with ultrafast tryptic digestion

ABSTRACT Monoclonal antibodies are subjected to a wide variety of post-translational modifications (PTMs) that cause structural heterogeneity. Characterization and control of these modifications or quality attributes are critical to ensure antibody quality and to define any potential effects on the ultimate safety and potency of antibody therapeutics. The biopharmaceutical industry currently uses numerous tools to analyze these quality attributes individually, which requires substantial time and resources. Here, we report a simple and ultrafast bottom-up liquid chromatography-mass spectrometry (uLC-MS) method with 5 min tryptic digestion to simultaneously analyze multiple modifications, including oxidation, deamidation, isomerization, glycation, glycosylation, and N-terminal pyro-glutamate formation, which can occur during antibody production in mammalian cell culture, during purification and/or on storage. Compared to commonly used preparation procedures, this uLC-MS method eliminates assay artifacts of falsely-increased Met oxidation, Asp isomerization, and Asn deamidation, a problem associated with long digestion times in conventional LC-MS methods. This simple, low artifact multi-attribute uLC-MS method can be used to quickly and accurately analyze samples at any stage of antibody drug development, in particular for clone and media selection during cell culture development.

[1]  Da Ren,et al.  Structure and stability changes of human IgG1 Fc as a consequence of methionine oxidation. , 2008, Biochemistry.

[2]  Catherine D. Kim,et al.  Determination of the origin of the N‐terminal pyro‐glutamate variation in monoclonal antibodies using model peptides , 2007, Biotechnology and bioengineering.

[3]  L. Zitvogel,et al.  Cancer: Antibodies regulate antitumour immunity , 2015, Nature.

[4]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[5]  Richard S Rogers,et al.  Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics , 2015, mAbs.

[6]  M. Matsumura,et al.  Isomerization of a single aspartyl residue of anti-epidermal growth factor receptor immunoglobulin gamma2 antibody highlights the role avidity plays in antibody activity. , 2008, Biochemistry.

[7]  W. Xu,et al.  Development of a sample preparation method for monitoring correct disulfide linkages of monoclonal antibodies by liquid chromatography-mass spectrometry. , 2016, Analytical biochemistry.

[8]  Guodong Chen,et al.  Structural mass spectrometry in biologics discovery: advances and future trends. , 2012, Drug discovery today.

[9]  J. M. Beals,et al.  In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. , 2005, Analytical chemistry.

[10]  Hongcheng Liu,et al.  A conventional procedure to reduce Asn deamidation artifacts during trypsin peptide mapping. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  A. Rathore,et al.  Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics. , 2015, Trends in biotechnology.

[12]  Wei Xu,et al.  High throughput peptide mapping method for analysis of site specific monoclonal antibody oxidation. , 2016, Journal of chromatography. A.

[13]  Yang Wang,et al.  Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. , 2011, Molecular immunology.

[14]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[15]  Thomayant Prueksaritanont,et al.  Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc gamma receptors. , 2009, Molecular immunology.

[16]  Nigel Jenkins,et al.  Post-translational Modifications of Recombinant Proteins: Significance for Biopharmaceuticals , 2008, Molecular biotechnology.

[17]  H. Yamaguchi,et al.  Enzyme‐immobilized reactors for rapid and efficient sample preparation in MS‐based proteomic studies , 2013, Proteomics.

[18]  R. Campbell,et al.  Degradation of aspartic acid and asparagine residues in human growth hormone-releasing factor. , 2009, International journal of peptide and protein research.

[19]  Hongcheng Liu,et al.  Structural effect of deglycosylation and methionine oxidation on a recombinant monoclonal antibody. , 2008, Molecular immunology.

[20]  Mohammed Shameem,et al.  Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications , 2014, mAbs.

[21]  W. Ens,et al.  Deamidation of -Asn-Gly- sequences during sample preparation for proteomics: Consequences for MALDI and HPLC-MALDI analysis. , 2006, Analytical chemistry.

[22]  Xue Han,et al.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. , 2015, The Journal of clinical investigation.

[23]  B. Karger,et al.  Comparability analysis of anti-CD20 commercial (rituximab) and RNAi-mediated fucosylated antibodies by two LC-MS approaches , 2013, mAbs.

[24]  Hongcheng Liu,et al.  Heterogeneity of monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[25]  B. Yan,et al.  Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain. , 2009, Journal of pharmaceutical sciences.

[26]  Huub Schellekens,et al.  Structure-Immunogenicity Relationships of Therapeutic Proteins , 2004, Pharmaceutical Research.

[27]  Gang Huang,et al.  Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn , 2009, Protein science : a publication of the Protein Society.

[28]  Mohammed Shameem,et al.  Analysis of monoclonal antibody oxidation by simple mixed mode chromatography. , 2016, Journal of chromatography. A.

[29]  A. Ambrogelly,et al.  Ultrafast and high-throughput N-glycan analysis for monoclonal antibodies , 2016, mAbs.

[30]  Hongcheng Liu,et al.  Accurate determination of protein methionine oxidation by stable isotope labeling and LC-MS analysis. , 2013, Analytical chemistry.

[31]  Ziping Wei,et al.  Identification of a single tryptophan residue as critical for binding activity in a humanized monoclonal antibody against respiratory syncytial virus. , 2007, Analytical chemistry.

[32]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[33]  Ying Zhang,et al.  A new tool for monoclonal antibody analysis , 2014, mAbs.

[34]  Li Zang,et al.  Residual metals cause variability in methionine oxidation measurements in protein pharmaceuticals using LC-UV/MS peptide mapping. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[35]  L. Weiner,et al.  Mechanisms of action of therapeutic antibodies for cancer. , 2015, Molecular immunology.

[36]  K. Brorson,et al.  Post-translational structural modifications of immunoglobulin G and their effect on biological activity , 2014, Analytical and Bioanalytical Chemistry.

[37]  Igor A Kaltashov,et al.  Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics. , 2012, Biotechnology advances.

[38]  S. Burman,et al.  Facile method of quantification for oxidized tryptophan degradants of monoclonal antibody by mixed mode ultra performance liquid chromatography. , 2012, Journal of chromatography. A.

[39]  Ronald T Borchardt,et al.  Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. , 2007, Biochemistry.

[40]  D. Chelius,et al.  Identification and characterization of oxidation and deamidation sites in monoclonal rat/mouse hybrid antibodies. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[41]  L. Presta,et al.  Isomerization of an aspartic acid residue in the complementarity-determining regions of a recombinant antibody to human IgE: identification and effect on binding affinity. , 1996, Biochemistry.

[42]  Alain Van Dorsselaer,et al.  Characterization of therapeutic antibodies and related products. , 2013, Analytical chemistry.

[43]  B. Warrack,et al.  Characterization of protein therapeutics by mass spectrometry: recent developments and future directions. , 2011, Drug discovery today.